Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21535
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 865–876 of 21,535 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Interventions
CardioMEMS HF System, HeartMate 3 Left Ventricular Assist System, Guideline Medical Directed Therapy
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
59
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 52 more
Conditions
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
Procedure · Radiation · Other + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
Conditions
HIV, Cancer, Chronic Granulomatous Disease, Dock 8 Deficiency
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
9
States / cities
Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Conditions
T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Interventions
CTX131
Biological
Lead sponsor
CRISPR Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Stanford, California • Boston, Massachusetts + 3 more
Conditions
Eating Disorders, Hypoestrogenemia
Interventions
17-β estradiol transdermal patches, Placebo Patch, Micronized progesterone 200 MG, Placebo Pill.
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions
Ruxolitinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Conditions
Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
Interventions
Hernia repair with mesh
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 80 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 5 more
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
241
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more
Conditions
Chronic Musculoskeletal Pain
Interventions
Pain Disengagement Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962
Conditions
Focal Epilepsy
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Conditions
Synovial Sarcoma, Myxoid Liposarcoma
Interventions
afamitresgene autoleucel (previously ADP-A2M4)
Genetic
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
17
States / cities
Duarte, California • Palo Alto, California • Aurora, Colorado + 13 more
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts